Endocrine Abstracts

Germline point mutations of the RET proto-oncogene are causative of hereditary MTC. Somatic mutations are described in 40% of sporadic MTCs. Although a relationship between somatic mutations and bad prognosis has been described, data are controversial.No date on the prognostic value of RET polymorphisms are available.Aim of the work was to verify if the presence of a somatic RET mutation and or a polymorphisms can influence the prognosis of MTC. This stu...

In a previous study we demonstrated that retinoic acid (RA) decreased the growth only of thyroid carcinoma cell lines expressing RA receptor β (RAR β) and that decitabine (5-Aza-CdR) re-induced RARβ expression. The aim of this study was to analyze the effects induced by the combined treatment with RA and 5-Aza-CdR in the same thyroid cancer cell lines.We studied the effect of 5-Aza-CdR 800 nM and RA 1 μM on the expression of thyroid s...

Mutations in the RET proto-oncogene are responsible for multiple endocrine neoplasia type II. Somatic RET mutations were described in 50% of medullary thyroid carcinoma (MTC). We describe here a novel germline mutation of the RET gene detected in an apparentely sporadic MTC.The index case was a 67 years old patient who arrived at our observation for a bilateral laterocervical linfoadenopathy. The patient was clinically evaluated for thyroid function and ...

About 10–15% of FNA cytologies are nondiagnostic, because of inadequate material or indeterminate (i.e. follicular neoplasms). Aim of this study was to analyse the practical usefulness of the analysis of BRAF mutations and RET/PTC rearrangements, known to be associated to papillary thyroid carcinoma (PTC), in FNA-material.We analysed 100 thyroid nodules with a nondiagnostic cytology: 75 follicular nodules and 25 cases with inadequate material. Fifte...

Objective: Currently, data about the molecular profile of multifocal papillary thyroid cancer (PTC) are still controversial. The aim of this study was to fully characterize by NGS the molecular profile of different histological variants in patients affected by multifocal PTCs.Methods: for this purpose, 12 multifocal PTC patients have been studied based to the following inclusion criteria: 1) a minimum of two tumors foci per patient with at least two diff...

Lenvatinib is a tyrosine kinase inhibitor (TKI), approved for the management of locally recurrent or metastatic, progressive, radioactive iodine–refractory differentiated thyroid cancer (DTC). A side effect of this drug is the tracheoesophageal fistula, described in 14.7% of patients. When this side effect is present, the interruption/withdrawn of the TKI is required and in this case no valid therapeutic options are described. We present the case of a 63-year-old woman pa...

Objectives: PET/CT scan with 18F-fluoro-dihydroxyphenylalanine (18F-DOPA) is an emerging useful tool in medullary thyroid cancer (MTC) patients. The question whether 18F-DOPA-PET/CT could be useful in MTC patients with biochemical incomplete response (BiR) is to clarify.Methods: Fifty-three MTC patients with BiR performed 18F-DOPA-PET/CT scan between May 2021 and December 2022 after having performed total body ...

Objectives: Currently 131I treatment after surgery is suggested in selected intermediate-risk and in high-risk patients with DTC. In patients with radio-avid structural disease and in those with biochemical disease a second 131I treatment could be considered. However data about the impact of the second 131I treatment on clinical status remains controversial.Methods: Clinical data of 231 DTC patients followed at the Unit o...

Background: Up to 2016, NIFT-P was considered a non-invasive encapsulated follicular variant of papillary thyroid carcinoma (FV-PTC) and was reclassified and downgraded to a pre-malignant lesion. However, if these nodules have peculiar ultrasonographic features able to pre-operatively suggest their histology is still a matter of discussion. We evaluated a large series of NIFT-P, FV-PTC, FTC, and FA to characterize their ultrasonographic features.Methods:...

Introduction: Hand-foot syndrome (HFS), or palmo-plantar erythrodysplasia, is an adverse event related to lenvatinib therapy. In the clinical trial (SELECT study) HFS was reported in 32% of patients, but only 3% was grade ≥3. In real-life studies the frequency was variable: between 8 and 55%.Patients: We collected clinical and pathological data about 165 patients with thyroid cancer treated with lenvatinib, followed up between 2012 and 2022 at the ...